Experienced in Purine Nucleoside Phosphorylase Deficiency

Dr. Jesal C. Patel

Hematology Oncology | Hematology | Oncology
Rocky Mountain Cancer Centers Llp
1800 Williams St, Suite 200, 
Denver, CO 
 (791.8 mi)
Offers Telehealth
Experienced in Purine Nucleoside Phosphorylase Deficiency
Rocky Mountain Cancer Centers Llp
1800 Williams St, Suite 200, 
Denver, CO 
 (791.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Jesal Patel is a Hematologist Oncology specialist and a Hematologist in Denver, Colorado. Dr. Patel and is rated as an Experienced provider by MediFind in the treatment of Purine Nucleoside Phosphorylase Deficiency. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, WT1-Related Wilms Tumor Syndromes, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in UT
Hospital Affiliations
Uch-Memorial Health System
Centura Health-Penrose St Francis Health Services
Heart Of The Rockies Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  UnitedHealthcare
  •  Humana

Locations

ROCKY MOUNTAIN CANCER CENTERS LLP
1800 Williams St, Suite 200, Denver, CO 80218
Other Locations
ROCKY MOUNTAIN CANCER CENTERS LLP
2312 N Nevada Ave, Suite 400, Colorado Springs, CO 80907
ROCKY MOUNTAIN CANCER CENTERS LLP
3027 N Circle Dr, Colorado Springs, CO 80909

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2

5 Total Publications

Simulation of ICD-9 to ICD-10-CM Transition for Family Medicine: Simple or Convoluted?
Simulation of ICD-9 to ICD-10-CM Transition for Family Medicine: Simple or Convoluted?
Journal: Journal of the American Board of Family Medicine : JABFM
Published: January 16, 2016

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile